ARTICLE | Clinical News
Galactoarabino-rhamnogalacturonate: Phase Ib started
July 28, 2014 7:00 AM UTC
Galectin said researchers at the Providence Portland Medical Center began an open-label, dose-escalation, U.S. Phase Ib trial to evaluate 1, 2, 4 and 8 mg/kg infusions of GR-MD-02 plus 3 mg/kg IV Yer...